Kiniksa Pharmaceuticals International, plc
KNSA
$40.59
$0.521.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.68% | 56.18% | 59.45% | 56.60% | 54.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.68% | 56.18% | 59.45% | 56.60% | 54.41% |
| Cost of Revenue | 88.65% | 95.97% | 107.09% | 110.41% | 92.76% |
| Gross Profit | 34.64% | 32.44% | 33.65% | 29.77% | 37.01% |
| SG&A Expenses | 9.63% | 16.44% | 24.30% | 29.81% | 36.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.43% | 43.23% | 49.55% | 58.69% | 53.12% |
| Operating Income | 245.43% | 116.27% | 48.26% | -81.04% | -36.43% |
| Income Before Tax | 390.74% | 179.14% | 70.73% | -117.10% | -36.39% |
| Income Tax Expenses | 265.93% | 221.58% | 135.21% | 122.91% | -37.46% |
| Earnings from Continuing Operations | 496.10% | 146.82% | -295.95% | -406.68% | -35.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 496.10% | 146.82% | -295.95% | -406.68% | -35.51% |
| EBIT | 245.43% | 116.27% | 48.26% | -81.04% | -36.43% |
| EBITDA | 262.46% | 123.47% | 49.78% | -92.17% | -45.01% |
| EPS Basic | 490.40% | 141.83% | -290.38% | -403.66% | -30.39% |
| Normalized Basic EPS | 378.49% | 174.55% | 71.14% | -111.82% | -34.40% |
| EPS Diluted | 421.42% | 123.71% | -322.82% | -425.98% | -27.50% |
| Normalized Diluted EPS | 355.15% | 163.39% | 68.02% | -111.25% | -33.57% |
| Average Basic Shares Outstanding | 3.31% | 2.81% | 2.34% | 1.95% | 1.53% |
| Average Diluted Shares Outstanding | 7.14% | 4.80% | 2.13% | 0.51% | 1.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |